Kornimate/medical-research-clean huggingface dataset:
the physalis child : identification of cognitive and emotional factors

Conditions: Auditory Hallucinations

Summary: the aim of this study is to show presence of cognitive and emotional factors on the beginning and persistence of auditory hallucinations in non-psychotic children. investigators will describe a significant link between this factors and hallucinations in a sample of non-psychotic children. the results of this sample will be comparing to another group of children of the same age, sex and diagnosis, but without hallucination. finally, investigators will control the persistence of hallucination on the first group after a six month period.

background: hallucinations are a common symptom in pediatric population without psychotic syndrome. vulnerability, co morbidity and risk factor are already been described. investigators will study the cognitive and emotional factors on the beginning and persistence of auditory hallucinations in non-psychotic children. the goal of the study is to find a social cognition our emotional impairment to explain auditory hallucinations without psychotic symptoms. methods: sample of out non-psychotic patients aged six to eighteen years old with auditory hallucinations were recruited with a self report scale created for this study. mini international neuropsychiatric interview (mini)-kids interview and "psychosis" section od kiddie-sads (schedule for affective disorders and schizophrenia for school age chidlren) were conducted to determine diagnostic and statistical manual of mental disorders (dsm) iv diagnoses. all children patient were spend specifics social cognition (neuropsychologic assessment nepsy ii) and emotional (ifferential emotions scale (des) iv, beliefs about voices questionnaire revised (bavq-r)) scales. each child results will be compared to child result of the same age, sex and diagnosis but without hallucination that passed the same specifics scales. all of child will be control after a six month period to evaluate auditory hallucination persistence and diagnosis evolution. the total period of the study will be twelve month.

Eligibility criteria:
inclusion criteria: * twenty participants included with auditory hallucination: * boy or girl * french * over six years old and under eighteen years old * dsm-iv diagnosis of mood disorder, anxiety, disruptive behavioral disorder, attention deficit hyperactivity disorder, without schizophrenia diagnosis, without mental retardation (intelligence quotient (iq)\>70), * parental and child consent, affiliated to social security. * twenty participants included without auditory hallucination: * boy or girl * french, * over six years old and under eighteen years old * dsm-iv diagnosis of mood disorder, anxiety, disruptive behavioral disorder, attention deficit hyperactivity disorder, without schizophrenia diagnosis, without mental retardation (iq\>70) * parental and child consent, affiliated to social security. exclusion criteria: * schizophrenia diagnosis, * neurologic, genetic or neurosensory disorders

Keywords: emotional auditory hallucinations non-psychotic children
comparison of ease of use and acceptability of intranasal and injectable glucagon among providers administering it to children or adolescents with type 1 diabetes (better-ing)

Conditions: Diabetes Mellitus, Type 1; Hypoglycemia

Summary: background : the benefits of good glycemic control are clearly established. however, achieving glycemic targets comes at the expense of the risk of hypoglycemia. repeated episodes of severe hypoglycemia can affect long-term cognitive function, especially in developing brains. fear of hypoglycemia, both in children and their parents, has an impact on participation in physical activity, quality of life and optimal diabetes control. during an episode of severe hypoglycemia, i.e., when accompanied by severe cognitive dysfunction requiring assistance from others, it is impossible to administer oral glucose. glucagon administration is particularly useful in this situation, as it rapidly raises blood glucose levels and restores consciousness. injectable glucagon was the only form approved in canada prior to 2019. a new formulation of glucagon for intranasal administration has recently been approved by health canada. the arrival of this formulation seems promising because of its ease of use while ensuring similar efficacy to injectable glucagon. furthermore, the ease of learning how to use each of the devices through a simple multimedia tool is unknown. indeed, current studies have not focused on a virtual teaching method. the latter is of particular interest in the context of a pandemic and in order to make information more accessible to a broader population that may not be present at family glucagon education (e.g., school-based caregivers). objective : compare the performance (time to prepare and administer, success rate) of the intranasal versus injectable glucagon administration procedure after a short video training 3 months earlier among parents/primary caregivers and school workers who may administer glucagon to children with type 1 diabetes. secondary objectives : 1. to assess stakeholder administration procedure preferences for the two glucagon formulations in the two groups ; 2. to explore the barriers and emotional impact (fears, perceptions, stress, etc.) related to the use of intranasal and injectable glucagon in both groups; 3. explore the participants' preferences in relation to the teaching method of administering the two forms of glucagon.


Eligibility criteria:
inclusion criteria: * parent or primary caregiver of a child or adolescent (\<18 years old) diagnosed with type 1 diabetes or * any adult who works or will work in a school or daycare setting who is likely to administer glucagon to a child or adolescent with type 1 diabetes (e.g. teachers, animators, teacher candidates, etc.) and * legal age * able to participate exclusion criteria: * working in the health field and teach glucagon injection or use it regularly in their duties * not understanding french (for viewing the videos)

Keywords: injectable glucagon intranasal glucagon
measurement of viscoelastic properties of bronchopulmonary secretions.

Conditions: Obstructive Pulmonary Disease

Summary: the study is experimental and aims to (a) compare the viscoelastic properties of bronchial secretions obtained in patients suffering from obstructive respiratory disease, and (b) to compare the viscoelastic properties of bronchial secretions obtained in patients before and after application of a respiratory physiotherapy or exercise as usually prescribed. after agreement, the sputum of the participants will be collected according to the method used in clinical routine.experiments (collection and analysis of sputum) will be conducted at the saint-luc university clinic.


Eligibility criteria:
inclusion criteria: * obstructive pulmonary disease exclusion criteria: * none
delivery, uptake and acceptability of hpv vaccination in tanzanian girls

Conditions: Cervical Cancer

Summary: the aims of this study are: 1. to determine feasibility of a school-based human papillomavirus (hpv) vaccination programme in tanzania. 2. to measure the uptake and acceptability of two different vaccination strategies in rural and urban schools. 3. to examine the characteristics of accepters/refusers of vaccination and to identify reasons for acceptance, refusal or non-completion. 4. to measure the cost of implementing a school-based hpv vaccination programme in tanzania.

vaccines against human papillomavirus infection, the primary cause of cervical cancer, are an attractive cervical cancer prevention strategy for resource poor settings which lack the infrastructure for establishing and maintaining complex screening programmes.feasibility and costs of setting up and sustaining an hpv vaccination programme will depend on whether it can be added onto an existing health programme within schools, if one exists, or whether it has to be established as a separate health intervention. other factors will also affect vaccine coverage. for example, uptake and overall effectiveness will be critically dependent on parental and community acceptability of a vaccine that prevents a sexually transmitted infection and how the vaccine is promoted and delivered by health-care providers will influence its uptake and acceptability. this study will determine feasibility, uptake and acceptability of different delivery strategies of school-based hpv vaccination in tanzania, examine factors related to acceptance or refusal of vaccination and measure the cost of implementing a school-based hpv vaccination programme in tanzania. three doses of quadrivalent human papillomavirus (hpv) vaccine, (gardasil®; merck \& co) given at 0, 2 and 6 months, will be provided to 5000 primary school girls at 134 randomly selected schools in mwanza region in tanzania. selected schools will be randomly assigned to one of two delivery strategies (age-based or class-based) and coverage and acceptability of these vaccine delivery strategies will be compared. qualitative research will be conducted before, during and after vaccination to examine barriers to vaccination and reasons for failure to complete vaccination as well as general community perceptions. to determine factors associated with refusal a case control study will be conducted on a 1:1 sample of 350 vaccine refusers and 350 accepters. the costs of introducing and scaling up hpv vaccines in schools will be estimated using established costing methods.

Eligibility criteria:
inclusion criteria: * female pupil * attends selected school * born in 1998 if enrolled in school selected for age-based delivery * attending standard (class) 6 if enrolled in school selected for class-based delivery exclusion criteria: * has not previously received hpv vaccine * has not participated in previous hpv vaccine trials

Keywords: human papillomavirus vaccine school girls tanzania acceptability vaccine coverage cervical cancer prevention
zambia integrated management of malaria and pneumonia study

Conditions: Pneumonia; Malaria

Summary: the purpose of the study is to demonstrate the effectiveness and feasibility of community-based management of pneumonia and malaria by community health workers (chws) in a rural district of zambia.

pneumonia and malaria are the two leading causes of morbidity and mortality among children under five in sub-saharan africa. due to limited access to health services in many developing countries, a number of global health organizations, including the world health organization, have strongly advocated the use of community health workers (chws) to deliver basic health care in the community and to facilitate referral to primary health facilities. existing supported chws in the study area will be trained in the assessment and classification of children between six months and five years of age presenting with fever and/or cough/difficult breathing. in the intervention arm, chws will be supplied with rapid diagnostic tests (rdts), coartem (a fixed dose combination of artemether-lumefantrine) and amoxicillin. the intervention chws will be trained to use rdts in patients with reported fever and provide those with a positive result with coartem; and patients suspected of pneumonia (based on fast breathing) will be treated with amoxicillin as per the standard of care at health facilities and monitored. in the control arm, no rdt will be performed. the chws will be supplied with coartem to treat malaria/febrile illness as per the integrated management of childhood illnesses (imci) guidelines and patients suspected of pneumonia will be referred to the health facility for treatment as per the current practice. data collectors will routinely visit chws to collect data on their consultations and follow-up patients treated by chws in their homes..

Eligibility criteria:
inclusion criteria: * age between 6 months and 5 years * present with history of fever or reported fever * present with cough or difficult breathing exclusion criteria: * age below 6 months and above 5 years * presence of signs and symptoms of severe illness

Keywords: community health care community health worker malaria pneumonia rapid diagnostic test
autologous intra-articular micro-fragmented adipose transfer for the treatment of thumb carpometacarpal joint arthritis

Conditions: Arthritis

Summary: 32 patients with eaton-glickel stage 2-3 cmc arthritis will be randomized to receive intraarticular mfat or intraarticular corticosteroid injection. patients with inflammatory arthritis or prior thumb base trauma or surgery will be excluded. autologous adipose tissue will be harvested from the outer thigh or lower abdomen using local anesthesia. tissue will be processed to remove oil and debris in-office using an fda-approved commercially available device. the processed adipose will be immediately injected into the thumb cmc joint under fluoroscopic guidance. visual analogue score (vas), grip/pinch strength, kapandji range of motion score, thumb disability examination, and quickdash score will be assessed pre-procedure and at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months.


Eligibility criteria:
inclusion criteria: 1. 18 years old or older; male and female patients 2. eaton-glickel stage 2-3 thumb cmc arthritis 3. failed conservative treatment (i.e. hand therapy, pain medications, splinting) 4. able to provide informed consent exclusion criteria: 1. pregnancy/breastfeeding 2. inflammatory or posttraumatic arthritis 3. prior thumb base trauma or surgery 4. evidence of skin infection or soft tissue loss at the thumb cmc joint or adipose harvest site 5. active local or systemic malignancy 6. known allergy to any study drug
effects of neurodynamics on lower extremity spasticity - a study in chronic stroke

Conditions: Chronic Stroke; Stroke; Spasticity Post Stroke

Summary: post-stroke spasticity in the lower extremity affects balance and gait, leading to decreased mobility and functional independence. therefore, effective intervention for reducing spasticity is crucial in stroke rehabilitation. recently, neurodynamics, though originally designed for pain management in orthopedic patients, has also been applied for treating spasticity in patients with neurological disorders. however, previous studies focused mainly on treating the upper extremity spasticity, but not on lower extremity spasticity, and not on possible neurophysiological changes. the present study aims to investigate the immediate effects of neurodynamics in reducing lower limb spasticity and neurophysiological changes in people with chronic stroke.

sample size calculation: there was no reference for the effect size of neurodymanics on reducing lower extremity spasticity, and the effect size of neurodynamics treatment for improving knee range of motion was between 0.89 to 2.55. we set the effect size of 0.6 (moderate effect size) with an alpha level of 5%, power at 80%, and a paired t-test model to calculate the sample size. statistical analysis: paired t-test will be used for within condition (experimental or control condition) comparisons. the change values between pre and post in each condition will be calculated and compared by paired t-test for between condition comparisons. the significance is set at p\< 0.05.

Eligibility criteria:
inclusion criteria: * diagnosis of first-ever stroke with unilateral lesion for more than 6 months * demonstrating calf muscle spasticity as indicated by modified ashworth scale equal to or greater than 1 * with passive rom of ankle dorsiflexion at least to neutral position (defined as 0°) * ability to walk at least 10m independently without a walking device or ankle-foot orthosis (afo) * sufficient cognition (mini-mental state examination, mmse score of 24 or higher) exclusion criteria: * contraindications to nerve conduction tests * other orthopedic and neurological disorders interfering participating in the study

Keywords: neurodynamics calf muscle spasticity chronic stroke
association of history of concussion with vestibular impairment and cognitive function in sports athletes

Conditions: Concussion, Mild; Vestibular Impairment; Cognitive Impairment

Summary: this study investigates the potential relationship between prior concussions and their impact on both vestibular function and cognitive abilities in athletes participating in sports.

the association of a history of concussions with vestibular impairment and cognitive function in sports athletes is a significant area of research due to the potential long-term consequences of head injuries in contact sports. vestibular impairment refers to disruptions in the balance and spatial orientation system of the inner ear, which can result from head trauma. cognitive function encompasses various mental processes, including memory, attention, and decision-making, which may be affected by concussions. this study aims to examine how prior concussions relate to both vestibular impairment and cognitive function in athletes participating in sports. researchers typically employ a combination of self-reported concussion history, clinical assessments of vestibular function, and standardized cognitive tests to evaluate participants. findings from such studies can provide valuable insights into the potential effects of concussions on athletes' balance, spatial awareness, and cognitive abilities. understanding these associations can inform concussion management protocols, rehabilitation strategies, and preventive measures in sports settings. furthermore, this research may contribute to the development of targeted interventions aimed at improving vestibular rehabilitation and cognitive training for athletes with a history of concussions. by identifying and addressing these potential deficits early, athletes may reduce their risk of long-term complications and optimize their performance and well-being in sports.

Eligibility criteria:
inclusion criteria: * athletes actively involved in sports at age of 18 to 35 * active players in contact sports exclusion criteria: * concussion other than sports * history of recent fractures. * participants having neurological deficits
efficacy and mechanisms of naltrexone+bupropion for binge eating disorder

Conditions: Binge-Eating Disorder

Summary: this study will test the efficacy of naltrexone hci and bupropion hci (nb) versus placebo in patients with binge-eating disorder (bed), with or without obesity.

binge-eating disorder (bed), the most prevalent formal eating disorder, is associated strongly with obesity and bio-psychosocial impairment. improved treatments for patients with bed are needed that can produce sustained clinical outcomes. this study aims to test the efficacy of naltrexone/bupropion (nb; fda-approved anti-obesity combination medication) for the treatment of bed in patients with and without obesity. the rct will provide new findings regarding the efficacy of nb medication for reducing binge-eating episodes among patients with bed, for reducing weight among patients with bed and obesity, and whether patients with and without obesity derive differential benefit from nb.

Eligibility criteria:
inclusion criteria: * binge eating disorder (full criteria as described in the american psychiatric association diagnostic and statistical manual of mental disorders, 5th edition); * bmi in the obesity (bmi \>30 and \ 21.5 and \<29.9) range; * available for the duration of the treatment and follow-up (15 months); * read, comprehend, and write english at a sufficient level to complete study-related materials. exclusion criteria: * currently taking opioid pain medications or drugs; or positive drug screen for opiates * currently taking medications that influence eating/weight; * history of seizures; * current substance use disorder or other severe psychiatric disturbance (e.g., suicidality); * past or current anorexia nervosa or bulimia nervosa; * pregnant or breastfeeding; * medical status judged by study physician as contraindication.
ovarian reserve in crohn's disease

Conditions: Crohn Disease; Ovary Disease; Anti-Mullerian Hormone Deficiency

Summary: crohn's disease reduces fertility by inducing inflammation both directly and in the fallopian tubes and ovaries and indirectly through surgical interventions and tubal adhesions associated with disease treatment. anti-mullerian hormone (amh) is a reliable indicator of ovarian reserve in women. the aim of this study was to compare serum amh levels in women with crohn's disease and healthy controls. in this study, the investigators aimed to investigate amh and ovarian capacity in the study group with crohn's disease and in the control group without disease.


Eligibility criteria:
inclusion criteria: * crohn's disease; * reproductive age women exclusion criteria: * over 40 years old, * a previous ovarian resection; * renal failure (serum creatinine levels n1.2 mg / dl);suspicion of malignancy; * the presence of hereditary or acquired hematological disease; * pregnancy; * current lactation; * the presence of a serious comorbid chronic disease; * cirrhosis originating from chronic liver disease; * abnormal thyroid function tests; * a known serious psychological problem; * presence of alcoholism and male sex.
a phase 2 study to evaluate the safety and efficacy of vs-505(ap301) to treat hyperphosphatemia in hemodialysis patients

Conditions: Hyperphosphatemia

Summary: a multi-center, open-label, parallel-design, active-controlled phase 2 study to evaluate the tolerability, safety and efficacy of various dosages of vs-505 compared with sevelamer carbonate when given orally with meal for 6 weeks to treat hyperphosphatemia in chronic kidney disease subjects receiving maintenance hemodialysis.

the main body of this study has 5 intervention arms, 4 vs-505 treatment arms of various dosage plus 1 active control arm of sevelamer carbonate, each consists 25 subjects. prior to this main part, a dose escalating cohort of 25 subjects is added to evaluate the tolerability of vs-505 in chinese patient population.

Eligibility criteria:
inclusion criteria: * adults with end stage renal disease who are receiving a stable hemodialysis regimen (3 times per week) with sufficient dialysis adequacy; * serum phosphorus level range from \>1.94 mmol/l (6.0 mg/dl) to ≤3.23 mmol/l (10.0 mg/dl) at the end of washout phase. exclusion criteria: * kidney transplant patient or scheduled kidney transplant, or change to peritoneal dialysis, home hemodialysis or plan to relocate to another dialysis center during the study period； * serum phosphorus level is \ 2.42 mmol/l（7.5 mg/dl) at screening, or documented to be \>3.23 mmol/l（10 mg/dl) within the latest three month prior to screening (screening included); * serum calcium level is \ 11 mg/dl at the screening; * serum immunoreactive parathyroid hormone (ipth)\>1000 pg/ml at the screening; * history of hemochromatosis or serum ferritin value ≥1000 μg/l at screening； * current clinically significant gastrointestinal (gi) disorder, or history of intestine obstruction, gastrectomy or duodenectomy, or gi tract surgery within 12 weeks prior to screening; * poorly controlled hypertension, cardiovascular disorders, and history of cerebrovascular disease or cardiovascular disease event within 24 weeks (6 months) prior to screening.